Navigation Links
Dana Farber Cancer Institute Donors Michael And Betsy Brauser Celebrate Success Of Inoperable Cervical Cancer Clinical Trials
Date:1/20/2017

Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in a clinical trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as she has been on the trial for more than six years, and her cancer has not worsened.

Betsy Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went to Dana-Farber when new tumors were found in her pelvic area. A biopsy confirmed the cancer had returned in an inoperable form. Betsy and her husband, Michael, were given two options: a standard chemotherapy repeat, or enroll in a new clinical trial comparing the drugs cediranib and olaparib (both in pill form), versus olaparib alone. For the Brausers, it was an easy choice. The clinical trial offered them the best opportunity to look toward the future.

The clinical trial’s leaders felt confident about its potential based on the two drugs involved. Cediranib is an angiogenesis inhibitor that prevents tumors from forming new blood vessels that help them grow and spread. Olaparib is part of a class of agents known as PARP inhibitors that was then starting to show promise in tumors that had trouble repairing damaged DNA.

QUOTE: “The combination of olaparib and cediranib has shown significant promise in the fight against ovarian cancer, It has been wonderful and very encouraging to see first-hand women like Betsy directly benefiting from this combination and our research here at Dana-Farber,” said Ursula Matulonis, MD, senior author of the trial and interim director of the Susan F. Smith Center.”

The study has since been expanded to many more women with recurrent ovarian cancer as a phase 2 trial, the report of which was ranked as the most influential publication of 2014 in breast, gynecologic, and obstetric disorders by the Columbia Hospital for Women Research Foundation.

QUOTE: “The results of these trials have suggested that oral combinations could be a vital part of how to combat ovarian cancer. We have now opened two large NCI-sponsored trials that will examine how the combination of cediranib and olaparib compares to standard chemotherapy as a treatment for the disease, said Dr. Joyce Liu, director of clinical research for Gynecologic Oncology at the Susan F. Smith Center. “

  • Michael and Betsy Brauser donate generously to a number of cancer research organizations. They have contributed $150,000 to the Dana Farber Cancer Institute and the Brigham and Women’s Hospital.

About The Dana Farber Cancer Institute

For nearly 70 years, The Dana Farber Cancer Institute led the world by making life-changing breakthroughs in cancer research and patient care. Each year, patients cross the globe to receive the most advanced care available, including over 700 innovative clinical trials. Their sole mission is to defeat cancer. Dana Farber’s donors and supporter generosity sustains the daily life of the Institute, allows physicians and caregivers to provide patients and families with the most advanced cancer therapies and support available, and encourages scientists to explore new ideas and discoveries. Donations to Dana Farber provides vital support paving the way for scientific discovery and compassionate care.

About Mr. Michael H. Brauser

Mr. Michael H. Brauser has been the Executive Chairman for Cogint, Inc. formerly IDI, Inc. since June 2015. From 1999 to 2002, he served as president and Chief Executive Officer of Naviant, Inc. (eDirect, Inc.) an internet marketing company. He also was a Founder of Seisint, Inc. (eData.com, Inc.). Mr. Brauser served as co-chairman of the Board of Directors of InterCLICK (now a part of Yahoo, Inc.) from August 2007 to December 2011. Mr. Brauser also served as co-chairman or the Board of Directors of ChromaDex, Inc., an innovative natural products company, from October 2011 to February 2015. Beyond his professional life, Michael Brauser supports his community by contributing to charitable organizations, nonprofits, and community groups. Mr. Brauser cofounded the Betsy and Michael Brauser Charitable Family Foundation, Inc., a charitable foundation that donates funds to a variety of causes.

RELATED LINKS

http://blog.dana-farber.org/insight/2016/07/clinical-trial-helps-florida-patient-betsy-brauser-live-with-ovarian-cancer/

Read the full story at http://www.prweb.com/releases/2017/01/prweb13992501.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Dr. Alan Farber Offers Attractive Solution for Gum Disease by Performing a New Type of Procedure, the LANAP® Protocol
2. Attorney Robert “RC” Pate Helping Improve the Lives of Children with Cancer
3. Boston Marathon Entries Available through the V Foundation for Cancer Research’s Fundraising Team
4. Imedex Certifies a Critical Review of Data Presented at Annual Breast Cancer Symposium During the 14th Annual Best of San Antonio: Breast Cancer – Bench to Bedside
5. PER® Announces Sandra Lee as Keynote Speaker for the 34th Annual Miami Breast Cancer Conference®
6. Cancer Screening Costs $88.7B Annually; New Tool Reduces Invasiveness and Price
7. European Perspectives in Lung Cancer Congress Promises to a be a Two-Day Practice-Changing Educational Event
8. United Breast Cancer Foundation Gift-in-Kind Community Service Program Update
9. American Lung Association Encourages Awareness of Underutilized Lung Cancer Testing Option through ‘Tell a Friend about Tumor Testing’
10. Cancer Correlated with History of Abuse and Trauma - with Researcher Carlos Caridad on Dr. Carol Francis Talk Radio
11. Dr. David Samadi Evaluates Prostate Cancer Treatment With Nonsurgical Light Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
Breaking Medicine Technology: